News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Brain Cancer Clinical Trial Gives Hope To Patients

Australian researchers have found that patients who received a cellular immunotherapy for the deadly brain cancer glioblastoma multiforme (GBM) in a clinical trial, on average survived longer than would have been expected without the treatment.

The team also found the treatment was safe and identified clues that will help them improve it in future.

GBM is the most common malignant brain tumour in adults. It is a particularly aggressive cancer that usually recurs quickly after treatment. Patients survive an average of 14-17 months after diagnosis.

The cellular immunotherapy was developed by the head of QIMR Berghofer’s Centre for Immunotherapy and Vaccine Development, Professor Rajiv Khanna AO, and his team.

It was tested in a phase I (safety) clinical trial of 25 patients at Briz Brain and Spine in collaboration with neurosurgeon Professor David Walker.

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Howard Davis: Roddy Doyle's Grim and Gritty Rosie

Although it was completed over two years ago, Roddy Doyle's first original screenplay in over eighteen years has only just arrived in New Zealand. It's been well worth the wait. More>>

Simon Nathan: No Ordinary In-Laws

The title of this short memoir by Keith Ovenden is misleading – it would be better called “Bill, Shirley and me” as it is an account of Ovenden’s memories of his parents-in-law, Bill Sutch and Shirley Smith. His presence is pervasive through the book. All three participants are (or were) eloquent, strongly-opinionated intellectuals who have made significant contributions to different aspects of New Zealand life. Their interactions were often complex and difficult... More>>

 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 


 
  • Wellington
  • Christchurch
  • Auckland